SLC5A2 and type 2 diabetes mellitus: However, the evidence in T2D is controversial; for example, in a meta-analysis of 10 randomized clinical trials involving 13,134 patients and 14 DKA events, overall event rates were 0.1% in the group of patients treated with SGLT2 inhibitors versus 0.06% in the control groups [104].